Excellerate Bioscience
Excellerate Bioscience is a Nottingham-based contract research organization providing molecular and cellular pharmacology services across the preclinical drug discovery pipeline, serving biotech SMEs, large pharma, and academic institutions with expertise in GPCR, kinase, and protein degradation assays.
- Company typePrivate
- Founded2016
- HeadquartersNottingham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Excellerate Bioscience does
Excellerate Bioscience is a UK-based contract research organization (CRO) founded in 2016 in Nottingham, specializing in molecular and cellular pharmacology services for preclinical drug discovery. The company designs, develops, and executes in vitro pharmacological assays covering target identification and validation, hit-to-lead screening, lead optimization, and preclinical candidate characterization, spanning target classes that include GPCRs, kinases, nuclear receptors, enzymes, and E3 ligases. Its technical platform integrates HTRF/TR-FRET, NanoBRET, real-time biosensor assays, high-content imaging, flow cytometry (up to 384-well), and Cisbio's Tag-lite technology for non-radioactive kinetic binding characterization, with data integration through Dotmatics and ActivityBase client platforms. Service offerings extend across therapeutic areas including immunology, metabolic disease, respiratory, oncology, CNS, inflammation, and cardiovascular, and cover drug modalities ranging from small molecules and covalent inhibitors to bispecific antibodies, PROTACs, and molecular glues.
Excellerate Bioscience firmographics
Firmographics- Name
- Excellerate Bioscience
- Legal name
- Excellerate Bioscience Ltd
- Website
- https://excelleratebio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Excellerate Bioscience is a Nottingham-based contract research organization providing molecular and cellular pharmacology services across the preclinical drug discovery pipeline, serving biotech SMEs, large pharma, and academic institutions with expertise in GPCR, kinase, and protein degradation assays.
- Ownership category
- akta.pro rank
Where Excellerate Bioscience is headquartered
LocationHeadquarters
- HQ city
- Nottingham
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Excellerate Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Fee-for-service laboratory services providing in vitro pharmacology, assay development, screening, and compound profiling across drug discovery phases. They offer both fee-for-service and monthly FTE (full-time equivalent) arrangements, with flexible costing approaches and go/no-go options at various project stages.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Fee-for-Service Model |
| Other | Monthly | Monthly FTE Arrangement |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Excellerate Bioscience product offering
Product offeringCore offering
Excellerate Bioscience is a UK-based contract research organisation (CRO) that provides in vitro pharmacology services for preclinical drug discovery. The company delivers molecular and cellular pharmacology assays, phenotypic assays, kinetic binding characterisation, and screening/assay development across drug target classes including GPCRs, kinases, nuclear receptors, enzymes, and E3 ligases. Services span the full drug discovery phases from target identification through preclinical candidate studies, offered via fee-for-service and monthly FTE arrangements.
Product overview
Excellerate Bioscience is a UK-based contract research organization (CRO) specializing in molecular and cellular pharmacology for preclinical drug discovery. The company offers an integrated portfolio of services across four drug discovery phases (Target Identification & Validation, Lead Identification, Lead Optimization, and Pre-Clinical Candidate Studies), supported by specialized assay platforms for Molecular Pharmacology, Phenotypic Assays, and Drug Modalities. Their service offerings span diverse therapeutic areas including immunology, oncology, respiratory, metabolic diseases, CNS, inflammation, and cardiovascular. The company operates through specialized capabilities including GPCR assay technologies, kinetic binding assay services, and screening and assay development, all delivered from state-of-the-art facilities at NG2 Business Park in Nottingham, UK.
Differentiator
Problem solved
Functional benefit
Products and services
- Target Identification & Validation
Quantifiable outcome
- 50+ clients served globally
- +2 more outcomes
Companies that use Excellerate Bioscience
Customer profileNamed customers11 records
Segments3 records
Ideal customer profiles3 records
Excellerate Bioscience technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature6 records
Excellerate Bioscience partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor, flagship and core.
- NG2 Business ParkminorState-of-the-art laboratory and office space location in central Nottingham, enabling expansion and enhanced CRO operations for the growing team.
- Atrogi ABflagshipEU Eurostars consortium (1 million euro award) for novel obesity therapeutics development. Excellerate contributes receptor pharmacology expertise and in vitro compound profiling. Consortium includes Stockholm and Maastricht universities and Latvian Institute of Organic Synthesis. Project ranked 31st out of 449 EU-wide applications.
- AdAlta LimitedcoreCollaboration to advance AdAlta's i-body pipeline using Excellerate's GPCR molecular pharmacology expertise. Excellerate profiles i-body leads to select superior candidates, evaluating binding, efficacy, safety and duration of action for GPCR targets.
- CisbiocoreStrategic partnership to deliver Tag-lite ligand kinetic binding assay services. Cisbio markets Excellerate's kinetic binding service across Europe while Excellerate operates the assays from Nottingham facility. Combines Tag-lite technology with Excellerate's pharmacology expertise for first-in-class compound kinetic characterisation.
- EU Kinetics for Drug Discovery (K4DD) ProgrammecoreCollaborative programme involving large pharma, SMEs and academia focused on advancing kinetics methodologies in drug discovery. Excellerate scientists actively contributed publications and methodological advances.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Excellerate Bioscience competitors and assessment
Company assessmentDirect peers
- SB Drug Discovery: UK-based CRO offering GPCR-focused assay development, screening, and profiling services for drug discovery. Highly comparable niche specialist in GPCR pharmacology serving similar biotech and pharma client base.
- Sygnature Discovery: UK-based integrated drug discovery CRO offering medicinal chemistry, in vitro pharmacology, and DMPK services to pharma and biotech clients. Most direct UK comparable to Excellerate in size and service scope, with similar focus on outsourced pharmacology for SMEs.
- Domainex: UK-based drug discovery CRO providing integrated services including assay development, medicinal chemistry, and in vitro pharmacology. Directly comparable to Excellerate as a UK-headquartered specialist CRO serving biotech SMEs with similar therapeutic area coverage.
- Reaction Biology: US-based preclinical CRO specializing in biochemical and cell-based assay services for drug discovery, with particular strength in kinases and other enzyme targets. Highly comparable to Excellerate's biochemical and cellular pharmacology services for SMEs and pharma clients.
- Pelago Bioscience: Swedish cell-based pharmacology CRO focused on cellular target engagement assays, including the Cellular Thermal Shift Assay (CETSA). Comparable niche specialist positioning in cellular pharmacology for early-stage drug discovery.
- Mercachem: Netherlands-based drug discovery CRO offering medicinal chemistry, in vitro pharmacology, and ADME services. Comparable European preclinical CRO with similar focus on integrated drug discovery support for SME and pharma clients.
Broad incumbents
- Charles River Laboratories: Global CRO offering end-to-end preclinical services including in vitro pharmacology, safety assessment, and manufacturing. Overlaps with Excellerate's in vitro pharmacology services but as one capability within a much broader discovery and development portfolio.
- Eurofins Discovery: Discovery services arm of Eurofins Scientific offering in vitro pharmacology, ADME, and compound screening at global scale. Directly competes in pharmacological assay services but with vastly larger scale, instrument fleets, and global footprint.
- Evotec: Global drug discovery CRO and platform company offering integrated services including in vitro pharmacology, screening, and drug discovery partnerships. Competes with Excellerate in outsourced pharmacology but with much broader service portfolio and public-company resources.
Others
- Cisbio: Technology partner and HTRF/Tag-lite reagent provider whose assays Excellerate uses to deliver kinetic binding services. Cisbio markets Excellerate's services across Europe, making it both a partner and an adjacent player in the kinetic binding assay ecosystem.
Market position
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Excellerate Bioscience social profiles
Digital presenceExcellerate Bioscience compliance and trust
Trust signalCompliance1 record
Excellerate Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Excellerate Bioscience leadership team
Management profileNumber of profiles
Profiles6 records
Excellerate Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Excellerate Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Excellerate Bioscience
What does Excellerate Bioscience do?
Excellerate Bioscience is a UK-based contract research organisation (CRO) that provides in vitro pharmacology services for preclinical drug discovery. The company delivers molecular and cellular pharmacology assays, phenotypic assays, kinetic binding characterisation, and screening/assay development across drug target classes including GPCRs, kinases, nuclear receptors, enzymes, and E3 ligases. Services span the full drug discovery phases from target identification through preclinical candidate studies, offered via fee-for-service and monthly FTE arrangements.
Is Excellerate Bioscience a public or private company?
Excellerate Bioscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Excellerate Bioscience founded?
Excellerate Bioscience was founded in 2016. It employs 11 to 50 people.
Where is Excellerate Bioscience based?
Excellerate Bioscience is headquartered in Nottingham, United Kingdom, in the Europe region.
How does Excellerate Bioscience make money?
One revenue line is on record: contract Research Services.
Who are Excellerate Bioscience's main competitors?
Direct peers on record are SB Drug Discovery, Sygnature Discovery, Domainex, Reaction Biology, Pelago Bioscience and Mercachem. Broad incumbents are Charles River Laboratories, Eurofins Discovery and Evotec. Cisbio is listed as an others.
Does Excellerate Bioscience have an API?
No public API is recorded for Excellerate Bioscience.